<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00521885</url>
  </required_header>
  <id_info>
    <org_study_id>LVH IRB# 2-20070508</org_study_id>
    <nct_id>NCT00521885</nct_id>
  </id_info>
  <brief_title>Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients</brief_title>
  <acronym>BRiEF</acronym>
  <official_title>Arixtra(Fondaparinux) vs. Lovenox (Enoxaparin) in Prevention of DVT in Acute Medically Ill, Non-surgical Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lehigh Valley Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lehigh Valley Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A total of 50 patients &gt;40 yrs of age with an expected hospital stay in the Medical Intensive
      Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled. The
      patient and study team will be blinded to which drug they are receiving (either Arixtra or
      Lovenox). Subjects will be examined for any bleeding complications. Subjects will receive
      drug for a total of 6-14 days while in the hospital. A follow up phone call will be performed
      by the study team approximately 30 days after discharge from the hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 50 patients will be enrolled in this double-blinded, randomized, controlled trial.
      Inclusion criteria: subjects&gt;40 yrs of age with an expected hospital stay in the Medical
      Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer (4 days
      bedridden) will be enrolled. Total drug treatment will be 6-14 days while in the hospital. A
      follow up phone call will be performed by the study team approximately 30 days after hospital
      discharge. Primary endpoint: bleeding rate (minor vs major) between study days 1-14.
      Secondary endpoint: DVT study days 1-14 (confirmed with LE duplex ultrasonogram).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study stopped due to lack of accrual
  </why_stopped>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding Rate Study Day 1-14 (Minor vs Major) With 30 Day f/u</measure>
    <time_frame>14 days</time_frame>
    <description>Bleeding Rate- Major bleeding defined as one or a combination of the following: Fatal; Bleeding at critical organ sites (intracranial, retroperitoneal, intraocular, pericardial, spinal or adrenal). Minor Bleeding defined as clinically overt bleeding that is not major bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Deep Vein Thrombosis</measure>
    <time_frame>14 Days</time_frame>
    <description>Confirmed by Lower Extremity Ultra-sonogram</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>Arixtra (Fondaparinox) 2.5 mg SC Daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arixtra (Fondaparinox) 2.5 mg SC Daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lovenox 40mg SC Daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lovenox 40mg SC Daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arixtra (Fondaparinox) 2.5 mg SC Daily</intervention_name>
    <description>Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm</description>
    <arm_group_label>Arixtra (Fondaparinox) 2.5 mg SC Daily</arm_group_label>
    <other_name>fondaparinux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lovenox 40mg SC Daily</intervention_name>
    <description>Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm</description>
    <arm_group_label>Lovenox 40mg SC Daily</arm_group_label>
    <other_name>enoxaparin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female &gt; 40 years of age.

          -  Pt with expected stay in hospital 6 days or &gt;, with expectation to be bedridden for &gt;
             4 days.

          -  Pts admitted to the MICU, Regional Heart Units of LV-MHC

        Exclusion Criteria:

          -  Surgical primary admission diagnosis

          -  Recent surgery within the past 12 weeks

          -  Planned surgery on the current admission

          -  Pregnancy

          -  Vent-dependent respiratory failure requiring intubation for &gt;24 hours.

          -  Known current DVT or PE prior to enrollment in study.

          -  Creatinine clearance &lt; 30 mL/min (calculated by the Cockcroft-Gault method) in a
             well-hydrated patient.

          -  Hx of prior or current lower upper or lower GI bleed.

          -  Platelet count &lt; 100,000 per cubic millimeter

          -  Current or prior anticoagulation within the prior 48 hours, excluding a single dose
             &amp;lor 24 hour period of prophylactic agent

          -  Bacterial endocarditis.

          -  Hemophilia

          -  Hypersensitivity to aspirin.

          -  Hypersensitivity to Arixtra or Lovenox

          -  Hx of hemorrhagic or ischemic stroke &lt; 3 months prior to enrolling

          -  Hematocrit &lt; 28%.

          -  SBP &gt;200 mmHg or DBP &gt;120 mmHg

          -  Positive for occult blood in stool.

          -  Admission to hospital for &gt; 48 hours prior to randomization

          -  Documented congenital or acquired bleeding disorder

          -  Indwelling intrathecal or epidural catheter

          -  Life expectancy &lt; 30 days

          -  Inability to have a flu assessment post-discharge from the hospital
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kruklitis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lehigh Valley Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lehigh Valley Hospital Muhlenberg</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2007</study_first_submitted>
  <study_first_submitted_qc>August 27, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2007</study_first_posted>
  <results_first_submitted>October 4, 2017</results_first_submitted>
  <results_first_submitted_qc>October 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 1, 2017</results_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bleeding rates</keyword>
  <keyword>Prophylaxis for deep vein thrombosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fondaparinux</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Unable to recruit suitable subjects is the reason this study was terminated early</recruitment_details>
      <pre_assignment_details>one patient was a screened failure- after consent found to have an exclusion criteria during screening</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arixtra (Fondaparinox) 2.5 mg Given Subcutaneously (SC) Daily</title>
          <description>In this arm subjects will be randomized to Arixtra (Fondaparinox) 2.5 mg given Subcutaneously (SC) once a day starting on day 1 and continuing through day 14 or day of discharge, whichever comes first.
Arixtra: Arixtra 2.5mg Sc Daily</description>
        </group>
        <group group_id="P2">
          <title>Lovenox 40mg Subcutaneously (SC) Daily</title>
          <description>Subjects will be randomized using a random generated listing of numbers with arm assignments associated with each assigned number. Only the study pharmacist will have access to this randomization code. All other study team members will remain blinded to the treatment arm. In this arm subjects will be randomized to Lovenox 40mg Subcutaneously (SC) Daily starting on day 1 and continuing through day 14 or day of discharge, whichever comes first.
Lovenox: Lovenox 40mg SC Daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arixtra (Fondaparinox) 2.5 mg Given SubCutaneously Daily</title>
          <description>Subjects may be randomized to Arixtra (Fondaparinox) 2.5 mg given SubCutaneously Daily starting on day 1 and continuing through day 14 or day of discharge, whichever comes first
Arixtra: Arixtra 2.5mg Sc Daily</description>
        </group>
        <group group_id="B2">
          <title>Lovenox 40mg SubCutaneously Daily</title>
          <description>Subjects may be randomized to Lovenox 40mg SubCutaneously Daily starting on day 1 and continuing through day 14 or day of discharge, whichever comes first
Lovenox: Lovenox 40mg SC Daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
          </count_list>
        </analyzed>
      </analyzed_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bleeding Rate Study Day 1-14 (Minor vs Major) With 30 Day f/u</title>
        <description>Bleeding Rate- Major bleeding defined as one or a combination of the following: Fatal; Bleeding at critical organ sites (intracranial, retroperitoneal, intraocular, pericardial, spinal or adrenal). Minor Bleeding defined as clinically overt bleeding that is not major bleeding.</description>
        <time_frame>14 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arixtra (Fondaparinox) 2.5 mg Given Subcutaneously (SC)Once a</title>
            <description>Arixtra (Fondaparinox) 2.5 mg given Subcutaneously (SC)once a day
Arixtra: Arixtra 2.5mg Sc Daily</description>
          </group>
          <group group_id="O2">
            <title>Lovenox 40mg Subcutaneously (SC) Daily</title>
            <description>Lovenox 40mg Subcutaneously (SC) Daily
Lovenox: Lovenox 40mg SC Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Rate Study Day 1-14 (Minor vs Major) With 30 Day f/u</title>
          <description>Bleeding Rate- Major bleeding defined as one or a combination of the following: Fatal; Bleeding at critical organ sites (intracranial, retroperitoneal, intraocular, pericardial, spinal or adrenal). Minor Bleeding defined as clinically overt bleeding that is not major bleeding.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Deep Vein Thrombosis</title>
        <description>Confirmed by Lower Extremity Ultra-sonogram</description>
        <time_frame>14 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arixtra (Fondaparinox) 2.5 mg Given Subcutaneously (SC)Once a</title>
            <description>Arixtra (Fondaparinox) 2.5 mg given Subcutaneously (SC)once a day
Arixtra: Arixtra 2.5mg Sc Daily</description>
          </group>
          <group group_id="O2">
            <title>Lovenox 40mg Subcutaneously (SC) Daily</title>
            <description>Lovenox 40mg Subcutaneously (SC) Daily
Lovenox: Lovenox 40mg SC Daily</description>
          </group>
        </group_list>
        <measure>
          <title>Deep Vein Thrombosis</title>
          <description>Confirmed by Lower Extremity Ultra-sonogram</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <desc>Does not differ</desc>
      <group_list>
        <group group_id="E1">
          <title>Arixtra (Fondaparinox) 2.5 mg Given SC Daily</title>
          <description>Arixtra (Fondaparinox) 2.5 mg given Subcutaneously (SC)once a day
Arixtra: Arixtra 2.5mg Sc Daily</description>
        </group>
        <group group_id="E2">
          <title>Lovenox 40mg SC Daily</title>
          <description>Lovenox 40mg Subcutaneously (SC) Daily
Lovenox: Lovenox 40mg SC Daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Began 2007 and ended 2009-1 subject enrolled-no SAE noted. No records which arm enrolled subject was assigned, so cannot accurately fill the patient flow section as &quot;1&quot; to match enroll number. Unknown what arm subject in. Only blinded pharm.was aware</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Leslie Baga, Director of Research</name_or_title>
      <organization>Lehigh Valley Health Network</organization>
      <phone>610 402 1285</phone>
      <email>Leslie.Baga@lvhn.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

